ATS International Conference 2026: key results and trends

Clinical worsening occurred in 18% (n = 64) of the ralinepag group and 36% (n = 121) of the placebo group (hazard ratio, 0.45; 95% confidence interval, 0.33-0.62; p < 0.0001).

The odds of reaching a category of greater percent OCS reduction at week 28 were higher with tezepelumab than placebo (cumulative odds ratio: 2.93 [95% confidence interval: 1.43, 6.03]; p=0.003).

For major morbidity/mortality events, sotatercept reduced the risk of a first event versus placebo (HR 0.39 [95% CI: 0.19-0.83]; P=0.006), with 12 sotatercept-treated versus 25 placebo-treated participants having ≥1 event.

Most TEAEs with oveporexton were urinary frequency (43 [61.4%]), insomnia (40 [57.1%]), and urinary urgency (10 [14.3%]).

The adjusted rate of achieving ≥ 2-point reduction in WCSS was 38% (95% CI: 31%-45%) in the paridiprubart group and 27% (95% CI: 21%-33%) in the placebo group, for an adjusted difference in proportions of 11% (p < 0.05).

Astegolimab was well tolerated, with comparable proportions of patients experiencing ≥1 AE across the 3 study arms (Q2W, 83.2%; Q4W, 87.9%; placebo, 85.5%).

Treatment-emergent adverse events occurred in 67.1% (itepekimab q2w), 68.2% (itepekimab q4w), and 68.4% (placebo) of patients in AERIFY-1 and in 64.3% (itepekimab q2w), 71.2% (itepekimab q4w), and 64.2% (placebo) of patients in AERIFY-2.

AD109 reduced AHI4 by ≥ 50% in 28.3% of participants (vs 17.7% with PBO; p < 0.0001); a higher proportion of participants receiving AD109 achieved disease control (AHI4<5; p < 0.0001).

The annualized rate of moderate/severe exacerbations treated with SCS was significantly reduced by 25% with mepolizumab versus placebo (rate ratio [RR] [95% confidence interval (CI)]: 0.75 [0.67, 0.85]).

In SWIFT-1/-2 (N = 762), depemokimab reduced exacerbations by 54% versus placebo (rate ratio [95% CI]: 0.46 [0.36, 0.59]); in the depemokimab group, AER (95% CI) over 52 weeks was 0.36 (0.27, 0.48) for medium-dose ICS subgroup and 0.65 (0.53, 0.79) for high-dose ICS subgroup.

Serious AEs occurred in 15.1% (76/504) of patients, among which 2.4% (12/504) were benralizumab-related.

Serious adverse events were reported in 6.2% (4/65) participants in the bedaquiline regimen and 3.1% (2/64) participants in control up to Week 24.